Clinical Trial Search

Primary: Change From Baseline to Week-26 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog 11) — 2.0; 2.5; 2.6 score on a scale — p=0.41

Primary: Diurnal Level 2 Hypoglycemia Events (ADA, <54 mg/dL) as Measured by CGM in Patients With Severe Hyperinsulinemic Hypoglycemia (HH) — 5.2; 5.2; 2.7; 2.1 events per 14…

Primary: Objective Response Rate (ORR) by Investigator — 4.3; 5.0; 13.2; 0 Percent of participants

Primary: Fundus Autofluorescence Imaging to Measure the Rate of Change in Area of Geographic Atrophy — 0.41; 0.35 mm/year — p=0.39

Primary: Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) at 1 Year — 53; 84 percentage of survival probability

Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) Post First Vaccination — 70.9; 78.2; 27.3 percentage of participants

Primary: Percent of Patients Who Are Progression Free at 2 Years — 45.0; 36.4 percentage of participants

Primary: Number of Subjects With Objective Response Rate (ORR) in EEC or EOC Patients — 2; 0; 0; 0 participants

Primary: Neoadjuvant Rectal Cancer (NAR) Score — 12.6; 13.7; 14.1; 11.5 score on a scale — p=0.69

Primary: Number of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability of Nivolumab as Maintenance Therapy — 33 Participants

Primary: Visual Acuity - Continuous — -5.5 Letter seen on eye chart

Primary: Visual Acuity - Continuous — -6.1; -1.6; 2.4 Letters seen

Primary: Number of Participants Meeting Criteria for Each of the 8 Ordinal Scale Categories on Day 8 — 11; 15; 24; 28 Participants — p=0.090

Primary: Number of Subjects With No Cells Observed Following Slit Lamp Examination From Baseline to Week 8 — 23; 21; 23; 21 Participants

Primary: Annualized Relapse Rate Before Cetirizine — 0.4; 0.1 relapses per year